Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Multiple marker detection in peripheral blood for NSCLC diagnosis.

Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W.

PLoS One. 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401.

2.

Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.

Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D, Carbonelli C, De Franco S, Brini M, Sgarbi G, Lodi R.

Lung Cancer. 2009 Apr;64(1):92-7. doi: 10.1016/j.lungcan.2008.07.012.

PMID:
18804892
3.

Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer.

Chiappetta C, Anile M, Leopizzi M, Venuta F, Della Rocca C.

Clin Chim Acta. 2013 Oct 21;425:93-6. doi: 10.1016/j.cca.2013.07.014.

PMID:
23892142
4.

Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.

Sher YP, Shih JY, Yang PC, Roffler SR, Chu YW, Wu CW, Yu CL, Peck K.

Clin Cancer Res. 2005 Jan 1;11(1):173-9.

5.

Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.

Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E.

Chest. 1995 Jul;108(1):163-9.

PMID:
7541742
6.

Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.

Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W.

Int J Mol Sci. 2013 May 16;14(5):10332-42. doi: 10.3390/ijms140510332.

7.

Quantification of free circulating DNA as a diagnostic marker in lung cancer.

Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U.

J Clin Oncol. 2003 Nov 1;21(21):3902-8.

PMID:
14507943
8.

The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer.

Du YZ, Gu XH, Li L, Gao F.

J Surg Oncol. 2011 Dec;104(7):836-40. doi: 10.1002/jso.21948.

PMID:
21656524
9.

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study.

Ma Z, Li H, Wang B, Shen Q, Cui E, Min L, Qian F, Ping J, Dai L.

J Cancer Res Clin Oncol. 2013 Apr;139(4):557-62. doi: 10.1007/s00432-012-1357-1.

PMID:
23224432
10.

Plasma microRNAs as potential biomarkers for non-small-cell lung cancer.

Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F.

Lab Invest. 2011 Apr;91(4):579-87. doi: 10.1038/labinvest.2010.194.

11.

Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer.

Sheu CC, Chang MY, Chang HC, Tsai JR, Lin SR, Chang SJ, Hwang JJ, Huang MS, Chong IW.

Oncology. 2006;70(3):203-11.

PMID:
16809939
12.

Serum microRNA biomarkers for detection of non-small cell lung cancer.

Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, Ochs MF, Ahrendt SA, Mambo E, Califano JA.

PLoS One. 2012;7(2):e32307. doi: 10.1371/journal.pone.0032307.

13.

Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis.

Devriese LA, Bosma AJ, van de Heuvel MM, Heemsbergen W, Voest EE, Schellens JH.

Lung Cancer. 2012 Feb;75(2):242-7. doi: 10.1016/j.lungcan.2011.07.003.

PMID:
21820198
14.

Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer.

Cheng M, Chen Y, Yu X, Tian Z, Wei H.

BMC Cancer. 2008 May 31;8:156. doi: 10.1186/1471-2407-8-156.

15.

Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.

Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H.

PLoS One. 2012;7(6):e38248. doi: 10.1371/journal.pone.0038248.

16.
17.

Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.

Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, Daimon T, Yamakado M, Imamura F, Kodama K.

BMC Cancer. 2010 Dec 22;10:690. doi: 10.1186/1471-2407-10-690.

18.

Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.

Yuxia M, Zhennan T, Wei Z.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2045-50. doi: 10.1007/s00432-012-1285-0.

PMID:
22806310
19.

Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer.

Wang Z, Cai M, Weng Y, Zhang F, Meng D, Song J, Zhou H, Xie Z.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1353-61. doi: 10.1007/s00432-014-1903-0.

PMID:
25544672
20.

Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A.

J Clin Oncol. 2004 Oct 15;22(20):4157-64.

PMID:
15483026
Items per page

Supplemental Content

Support Center